ShadowBuys

Federal Register · Regulatory notice

Certain Clear Aligners and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Granting In Part a Motion To Amend the Complaint and Notice of Investigation

Notice is hereby given that the U.S. International Trade Commission has determined not to review the presiding chief administrative law judge's ("CALJ") initial determination ("ID") (Order No. 11) granting a motion to amend the complaint and notice of investigation ("NOI") to (1) add allegations of infringement of claim 24 for U.S. Patent No. 11,766,313 ("the `313 patent"); (2) add allegations of infringement of claim 28 for U.S. Patent No. 11,766,314 ("the `314 patent"); (3) add allegations of infringement of claims 2 and 14 for U.S. Patent No. 8,866,977 ("the `977 patent"); and (4) add allegations of infringement of claim 9 for U.S. Patent No. 10,980,616 ("the `616 patent").

Follow ALGN
Became public
Jun 8, 2026
Event / period date
Not stated
Collected
Nov 8, 2026, 7:46 PM EST

Why this is connected

The source explicitly mentions ALIGN TECHNOLOGY INC. A mention alone does not establish a financial benefit.

Source evidence

Read the source excerpt or record
s://edis.usitc.gov . For help accessing EDIS, please email [email protected] . General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov . Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205-1810. SUPPLEMENTARY INFORMATION: On December 29, 2025, the Commission instituted this investigation based on a complaint filed by Align Technology, Inc. of Tempe, Arizona (``Align''). 90 FR 245 (Dec. 29, 2025). The complaint alleged violations of section 337 of the Tariff Act of 1930, as amended, based on the importation into the United States, the sale for importation, or the sale within the United States after importation of certain clear aligners and components thereof by reason of infringement of one or more of claims 1 and 16 of the `313 patent; claims 1, 11, and 21 of the `314 patent; claims 1 and 9 of the `977 patent; claim 1 of U.S. Patent No. 12,059,321; claims 1, 12, and 20 of the `616 patent; and claims 1, 17, and 21 of U.S. Patent No. 11,490,996 (``the `996 patent''). Id. The Commission's notice of investigation named the following respondents: Angelalign Technology Inc. of Shanghai, China; Wuxi EA Medical Instruments of Jiangsu, China; Wuxi EA Bio-Tech Co., Ltd. of Jiangsu, China; Shanghai EA Medical Instruments Co.

Congressional trading in ALGN

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.